ATXI Avenue Therapeutics Inc.

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.

$1.97
As of 07/23/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/27/2017
Outstanding shares:  16,748,068
Average volume:  275,708
Market cap:   $35,003,462
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    05360L205
ISIN:        US05360L2051
Sedol:      BF0WLV8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.74
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy